Cancer tumor necrosis factor ligands

Fulda S, Debatin KM. 2004. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 64 337-346. 

Jung, E.M., Lim, J.H., Lee, T.J., Park, J., Choi, K.S. and Kwon, T.K. (2005) Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 (DR5). Cancer Biology 26(1 1), 1 905-1 91 3. 

IL-1 is stable, and it diffuses to and activates receptors (IL-1 receptors) on adjacent and distant cells. The IL-1 receptor of endothelial cells is especially important (Fig. 13.5a). In all cells, the IL-1 ligand bound to its receptor causes surface expression of a second cytokine, tumor necrosis factor-a (TNF-a). TNF-a was originally described as a factor that kills (causes necrosis of) mouse fibrosarcoma (cancer) cells but not normal mouse fibroblasts. TNF-a is released from the cell surface by an adamalysin protease, TNF alpha converting enzyme (TACE). TACE is also known as ADAM 17, one of more than 40 cell surface bound adamalysins related to the ADAM-TS2 subfamily (Sect. 8.2.1). Unlike IL-1, TNF-a is unstable and can only activate TNF receptors on nearby cells. It usually produces responses that supplement those from IL-1 activation (Fig. 13.5b). 

Deeb, D., Xu, Y.X., Jiang, H., Gao, X., Janakiraman, N., Chapman, R.A., and Gautam, S.C., Curcumin (diferuloy 1-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol. Cancer Then, 2(1), 95-103,... 

Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo21/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res. 2001 7 1362-1369. 

Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/ Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 2003 63(17) 5390-5400. 

Walczak H, Bouchon A, Stahl H, Krammer PH (2000) Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res 60 3051-3057... 

Jazirehi, A.R., Ng, C.P., Gan, X.H., Schiller, G., and Bonavida, B. (2001). Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2I-/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin. Cancer Res. 7, 3874-3883. 

Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001 61 3330-3338. 

---